BRPI0510170B8 - composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto - Google Patents

composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto

Info

Publication number
BRPI0510170B8
BRPI0510170B8 BRPI0510170A BRPI0510170A BRPI0510170B8 BR PI0510170 B8 BRPI0510170 B8 BR PI0510170B8 BR PI0510170 A BRPI0510170 A BR PI0510170A BR PI0510170 A BRPI0510170 A BR PI0510170A BR PI0510170 B8 BRPI0510170 B8 BR PI0510170B8
Authority
BR
Brazil
Prior art keywords
compound
acetylcholine receptor
treatment
pharmaceutical composition
muscarinic acetylcholine
Prior art date
Application number
BRPI0510170A
Other languages
English (en)
Inventor
W Mccleland Brent
E Neipp Christopher
Ibrahim Laine Dramane
R Palovich Michael
M Thomas Sonia
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0510170A publication Critical patent/BRPI0510170A/pt
Publication of BRPI0510170B1 publication Critical patent/BRPI0510170B1/pt
Publication of BRPI0510170B8 publication Critical patent/BRPI0510170B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/452—Piperidinium derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

antagonistas do receptor muscarínico de acetilcolina são fornecidos antagonistas do receptor muscarínico de acetilcolina e métodos de uso dos mesmos.
BRPI0510170A 2004-04-27 2005-04-27 composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto BRPI0510170B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56562304P 2004-04-27 2004-04-27
PCT/US2005/014386 WO2005104745A2 (en) 2004-04-27 2005-04-27 Muscarinic acetylcholine receptor antagonists

Publications (3)

Publication Number Publication Date
BRPI0510170A BRPI0510170A (pt) 2007-10-02
BRPI0510170B1 BRPI0510170B1 (pt) 2018-12-18
BRPI0510170B8 true BRPI0510170B8 (pt) 2021-05-25

Family

ID=35242158

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0510170A BRPI0510170B8 (pt) 2004-04-27 2005-04-27 composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto

Country Status (37)

Country Link
US (9) US7498440B2 (pt)
EP (3) EP2570128B1 (pt)
JP (2) JP5014121B2 (pt)
KR (2) KR101152032B1 (pt)
CN (2) CN1976701A (pt)
AP (1) AP2213A (pt)
AR (1) AR050902A1 (pt)
AU (1) AU2005237576B2 (pt)
BR (1) BRPI0510170B8 (pt)
CA (2) CA2564742C (pt)
CY (3) CY1113196T1 (pt)
DK (2) DK2570128T3 (pt)
EA (2) EA021994B1 (pt)
EC (1) ECSP066940A (pt)
ES (2) ES2392848T4 (pt)
HK (1) HK1102423A1 (pt)
HR (2) HRP20120832T1 (pt)
HU (2) HUE031304T2 (pt)
IL (1) IL178152A (pt)
LT (1) LT2570128T (pt)
LU (1) LU92565I2 (pt)
MA (1) MA28631B1 (pt)
MX (1) MXPA06012405A (pt)
MY (1) MY144753A (pt)
NL (1) NL300694I1 (pt)
NO (3) NO338959B1 (pt)
NZ (1) NZ549997A (pt)
PE (1) PE20060259A1 (pt)
PL (2) PL2570128T3 (pt)
PT (2) PT2570128T (pt)
SG (1) SG186597A1 (pt)
SI (2) SI1740177T1 (pt)
TW (1) TWI363759B (pt)
UA (1) UA95768C2 (pt)
UY (1) UY28871A1 (pt)
WO (1) WO2005104745A2 (pt)
ZA (1) ZA200608565B (pt)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
EA200600787A1 (ru) * 2003-10-17 2006-08-25 Глэксо Груп Лимитед Антагонисты мускариновых ацетилхолиновых рецепторов
PE20050489A1 (es) * 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
EP1725236A4 (en) * 2004-03-11 2009-05-13 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
JP2007529513A (ja) * 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
US20070185148A1 (en) * 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
CA2563109A1 (en) * 2004-04-05 2006-08-17 Samaritan Pharmaceuticals, Inc. Anti-hiv quinuclidine compounds
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007537261A (ja) * 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
JP2008520579A (ja) * 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
WO2007016639A2 (en) * 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937068A4 (en) * 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
EA200801997A1 (ru) 2006-04-20 2009-04-28 Глаксо Груп Лимитед Новые соединения
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
NZ574533A (en) 2006-08-01 2011-05-27 Glaxo Group Ltd Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors
AR065804A1 (es) 2007-03-23 2009-07-01 Smithkline Beecham Corp Compuesto de indol carboxamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar un medicamento
PE20091552A1 (es) 2008-02-06 2009-10-25 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
PE20091563A1 (es) 2008-02-06 2009-11-05 Glaxo Group Ltd Farmacoforos duales - antagonistas muscarinicos de pde4
CL2009000248A1 (es) 2008-02-06 2009-09-11 Glaxo Group Ltd Compuestos derivados de pirazolo [3,4-b] piridin-5-il, inhibidores de la fosfodiesterasa de tipo iv (pde4) y antagonista de receptores muscarinicos de acetilcolina (machr); composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles en el tratamiento de enferemedades respiratorias y alergicas
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
US8163743B2 (en) 2008-06-05 2012-04-24 GlaxoGroupLimited 4-carboxamide indazole derivatives useful as inhibitors of PI3-kinases
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
US11116721B2 (en) 2009-02-26 2021-09-14 Glaxo Group Limited Pharmaceutical formulations comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl) phenol
ES2542551T3 (es) 2009-03-09 2015-08-06 Glaxo Group Limited 4-Oxadiazol-2-il-indazoles como inhibidores de PI3 cinasas
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
EA021056B1 (ru) 2009-04-30 2015-03-31 Глаксо Груп Лимитед Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ, содержащая их фармацевтическая композиция и их применение в лечении расстройств, опосредованных ненадлежащей активностью pi3-киназ
WO2011029896A1 (en) 2009-09-11 2011-03-17 Glaxo Group Limited Methods of preparation of muscarinic acetylcholine receptor antagonists
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
JP2013512879A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤としてのベンズピラゾール誘導体
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP2528921B1 (en) * 2010-01-28 2017-10-18 Theron Pharmaceuticals, Inc. 7-azoniabicyclo [2.2.1]heptane derivatives, methods of production, and pharmaceutical uses thereof
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
PE20130282A1 (es) * 2010-06-22 2013-03-25 Chiesi Farma Spa Formulacion en polvo seca que comprende una droga antimuscarinica
DK2614058T3 (en) 2010-09-08 2015-09-28 Glaxosmithkline Ip Dev Ltd Polymorphs, and the salts of N- [5- [4- (5 - {[(2R, 6S) -2,6-dimethyl-4-morpholinyl] methyl} -1,3-oxazol-2-yl) -1H-indazole -6-yl] -2- (methyloxy) -3-pyridinyl] methanesulfonamide.
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
EA201391618A1 (ru) 2011-06-08 2014-05-30 Глаксо Груп Лимитед Комбинация, содержащая умеклидиний и кортикостероид
KR20140041700A (ko) 2011-06-08 2014-04-04 글락소 그룹 리미티드 우메클리디늄을 포함하는 건조 분말 흡입기 조성물
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
RU2502743C1 (ru) * 2012-08-03 2013-12-27 Федеральное государственное бюджетное учреждение "Российский кардиологический научно-производственный комплекс" Министерства здравоохранения и социального развития РФ (ФГБУ "РКНПК" Минздравсоцразвития России) Синтетический антиген, обладающий способностью связывать аутоантитела к мускариновому м2-рецептору
IN2015KN00323A (pt) * 2012-08-15 2015-07-10 Glaxo Group Ltd
GB201222679D0 (en) 2012-12-17 2013-01-30 Glaxo Group Ltd Pharmaceutical combination products
AU2014292722B2 (en) * 2013-07-13 2017-03-09 Beijing Showby Pharmaceutical Co., Ltd. Quinine compounds, and optical isomers, preparation method and medical use thereof
EP3027184A1 (en) 2013-07-30 2016-06-08 GlaxoSmithKline Intellectual Property Development Limited Topical compositions for treatment of excessive sweating and methods of use thereof
CA2923995A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
CN107072976A (zh) 2014-05-12 2017-08-18 葛兰素史克知识产权第二有限公司 用于治疗传染性疾病的包含Danirixin的药物组合物
EP3650019B8 (en) 2014-05-28 2023-10-11 GlaxoSmithKline Intellectual Property Development Limited Fluticasone furoate in the treatment of copd
ES2751698T3 (es) * 2014-11-03 2020-04-01 Olon Spa Procedimiento para la preparación del éster etílico del ácido 1-(2-halogen-etil)-4-piperidina-carboxílico
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
CN105461710A (zh) * 2015-10-23 2016-04-06 安徽德信佳生物医药有限公司 一种芜地溴铵的制备方法
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN107200734B (zh) * 2016-03-18 2019-12-24 益方生物科技（上海）有限公司 奎宁环衍生物及其制备方法和用途
EP3248970A1 (en) 2016-05-27 2017-11-29 Zentiva K.S. Forms of umeclidinium bromide
JP2019524792A (ja) 2016-08-08 2019-09-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
PT109740B (pt) 2016-11-14 2020-07-30 Hovione Farmaciencia Sa Processo para a preparação de brometo de umeclidínio
WO2018163212A1 (en) * 2017-03-08 2018-09-13 Gbr Laboratories Pvt. Ltd A process for the preparation of umeclidinium bromide and intermediates thereof
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
IT201700058796A1 (it) * 2017-05-30 2018-11-30 Olon Spa Procedimento per la preparazione di un nuovo intermedio di sintesi dell’umeclidinio.
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
CN108558860B (zh) * 2018-06-04 2020-12-25 成都伊诺达博医药科技有限公司 一种合成芜地溴铵的方法
US11484531B2 (en) 2018-08-30 2022-11-01 Theravance Biopharma R&D Ip, Llc Methods for treating chronic obstructive pulmonary disease
PT115583B (pt) 2019-06-17 2022-05-02 Hovione Farm S A Processo contínuo para a preparação de medicamentos anticolinérgicos
CN113387923A (zh) * 2020-03-13 2021-09-14 诺华股份有限公司 硫辛酸胆碱酯盐的药物组合物及使用其的治疗方法
US20240066037A1 (en) 2020-03-26 2024-02-29 Glaxosmithkline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
CN111484445B (zh) * 2020-04-21 2021-05-18 广东莱佛士制药技术有限公司 分离纯化高纯度乌美溴铵的中间体的方法
KR20230004640A (ko) * 2020-04-26 2023-01-06 베이징 서우바이 파마슈티컬 컴퍼니 리미티드 M 수용체 길항제의 결정 및 이의 제조 방법 및 이의 응용
EP4211171A2 (en) 2020-09-10 2023-07-19 Precirix N.V. Antibody fragment against fap
CN112479983B (zh) * 2020-11-25 2022-07-12 江苏豪森药业集团有限公司 乌美溴铵中间体及其制备方法
PT117440A (pt) 2021-09-03 2023-03-03 Hovione Farm S A Processo para a preparação de aminas cíclicas cloroaquilo substituídas
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
WO2023213801A1 (en) 2022-05-02 2023-11-09 Precirix N.V. Pre-targeting

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2800481A (en) * 1955-07-01 1957-07-23 Smith Kline French Lab Tertiary alcohol derivatives of 8-alkylnortropanes and the acid and quaternary ammonium salts thereof
US2800478A (en) 1955-07-01 1957-07-23 Smith Kline French Lab 3-substituted-8-alkylnortropanes and the acid and quaternary ammonium salts thereof
AT298118B (de) 1967-06-08 1972-04-25 Siemens Ag Verfahren zur Umsetzung von Spannungen in digitale Werte und Vorrichtung zur Durchführung des Verfahrens
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1230087A (pt) 1967-08-17 1971-04-28
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
CY1308A (en) 1979-12-06 1985-12-06 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
FI79651C (fi) 1982-10-08 1990-02-12 Glaxo Group Ltd Doseringsanordning foer medicin.
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
GR861995B (en) 1985-07-30 1986-11-04 Glaxo Group Ltd Devices for administering medicaments to patients
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
US5780466A (en) 1995-01-30 1998-07-14 Sanofi Substituted heterocyclic compounds method of preparing them and pharmaceutical compositions in which they are present
EP0944626A4 (en) 1996-12-02 2002-09-04 Univ Georgetown TROPANE DERIVATIVES AND SYNTHESIS METHOD
US6248752B1 (en) 1998-02-27 2001-06-19 Charles Duane Smith Azabicyclooctane compositions and methods for enhancing chemotherapy
US6262066B1 (en) 1998-07-27 2001-07-17 Schering Corporation High affinity ligands for nociceptin receptor ORL-1
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
BR0116624A (pt) * 2000-12-28 2003-12-23 Almirall Prodesfarma Ag Composto, processo para produzir o mesmo, composição farmacêutica, uso do composto ou da composição farmacêutica, e, produto de combinação
US7361668B2 (en) 2001-10-17 2008-04-22 Ucb, S.A. Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
EP1442037A1 (en) * 2001-11-09 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
CN1832948B (zh) * 2001-12-20 2011-06-15 基耶西药品股份公司 1-烷基-1-氮*双环[2.2.2]辛烷氨基甲酸酯衍生物及其用作蕈毒碱受体拮抗剂的用途
US6696462B2 (en) 2002-01-31 2004-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Anticholinergics, processes for the preparation thereof, and pharmaceutical compositions
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
ES2204295B1 (es) * 2002-07-02 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de quinuclidina-amida.
TW200410951A (en) 2002-08-06 2004-07-01 Glaxo Group Ltd M3 muscarinic acetylcholine receptor antagonists
US7232841B2 (en) 2003-04-07 2007-06-19 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
AR045914A1 (es) * 2003-07-17 2005-11-16 Glaxo Group Ltd Compuesto alcoholico terciario del 8-azoniabiciclo [3.2.1] octano, composicion farmaceutica que lo comprende y su uso para preparar esta ultima
AR045913A1 (es) 2003-07-17 2005-11-16 Glaxo Group Ltd Derivados olefinicos de 8-azabiciclo[3,2,1]octanos como antagonistas de receptores muscarinicos de acetilcolina
AR048573A1 (es) 2003-07-17 2006-05-10 Glaxo Group Ltd Compuesto de 8-azoniabiciclo[3.2.1]octano sustituido en la posicion 3, composicion farmceutica que lo comprende y su uso para preparar esta ultima
KR20080067023A (ko) 2003-10-14 2008-07-17 글락소 그룹 리미티드 무스카린성 아세틸콜린 수용체 길항제
EA200600787A1 (ru) 2003-10-17 2006-08-25 Глэксо Груп Лимитед Антагонисты мускариновых ацетилхолиновых рецепторов
PE20050489A1 (es) 2003-11-04 2005-09-02 Glaxo Group Ltd Antagonistas de receptores de acetilcolina muscarinicos
DE602004021959D1 (de) 2003-11-21 2009-08-20 Theravance Inc Verbindungen mit agonistischer wirkung am beta2-adrenergen rezeptor und am muscarinischen rezeptor
PE20050861A1 (es) 2003-12-03 2005-12-10 Glaxo Group Ltd Derivados de sales ciclicas de amonio cuaternario como antagonistas del receptor muscarinico de acetilcolina
PE20050897A1 (es) 2003-12-03 2005-11-06 Glaxo Group Ltd Nuevos antagonistas del receptor muscarinico m3 de acetilcolina
TW200534855A (en) 2004-01-13 2005-11-01 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007530451A (ja) 2004-03-11 2007-11-01 グラクソ　グループ　リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
EP1725236A4 (en) 2004-03-11 2009-05-13 Glaxo Group Ltd NEW M3 MUSCARIN ACETYLCHOLINE RECEPTOR ANTAGONISTS
EP1725240A4 (en) 2004-03-17 2009-03-25 Glaxo Group Ltd ANTAGONISTS OF THE ACETYLCHOLINE MUSCARINIC RECEPTOR
US20070185148A1 (en) 2004-03-17 2007-08-09 Glaxo Group Limited M3 muscarinic acetylchoine receptor antagonists
US20070185088A1 (en) 2004-03-17 2007-08-09 Jakob Busch-Petersen M3 muscarinic acetylchoine receptor antagonists
JP2007529513A (ja) 2004-03-17 2007-10-25 グラクソ　グループ　リミテッド Ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
JP2007538005A (ja) 2004-04-07 2007-12-27 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
TWI363759B (en) 2004-04-27 2012-05-11 Glaxo Group Ltd Muscarinic acetylcholine receptor antagonists
JP2007537261A (ja) 2004-05-13 2007-12-20 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
JP2008501020A (ja) 2004-05-28 2008-01-17 グラクソ　グループ　リミテッド ムスカリン性アセチルコリン受容体アンタゴニスト
US20080287487A1 (en) 2004-06-30 2008-11-20 Anthony William James Cooper Muscarinic Acetylcholine Receptor Antagonists
WO2006017768A2 (en) 2004-08-05 2006-02-16 Glaxo Group Limited Muscarinic acetylcholine receptor antagonists
US20090076061A1 (en) 2004-08-06 2009-03-19 Jakob Busch-Petersen Muscarinic acetycholine receptor antagonists
US20090258858A1 (en) 2004-10-29 2009-10-15 Jakob Busch-Petersen Muscarinic acetylcholine receptor antagonists
US20090142279A1 (en) 2004-11-15 2009-06-04 Budzik Brian W Novel m3 muscarinic acetylcholine receptor antagonists
JP2008520579A (ja) 2004-11-15 2008-06-19 グラクソ グループ リミテッド 新規ｍ３ムスカリン性アセチルコリン受容体アンタゴニスト
PE20061162A1 (es) 2004-12-06 2006-10-14 Smithkline Beecham Corp Compuestos derivados olefinicos de 8-azoniabiciclo[3.2.1]octanos
PE20060826A1 (es) 2004-12-06 2006-10-08 Smithkline Beecham Corp Derivado oleofinico de 8-azoniabiciclo[3.2.1]octano y combinacion farmaceutica que lo comprende
WO2006065788A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Novel muscarinic acetylcholine receptor antagonists
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007018514A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetylcholine receptor antagonists
WO2007018508A1 (en) 2005-07-28 2007-02-15 Glaxo Group Limited Novel m3 muscarinic acetycholine receptor antagonists
WO2007016639A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
WO2007016650A2 (en) 2005-08-02 2007-02-08 Glaxo Group Limited M3 muscarinic acetylcholine receptor antagonists
EP1937068A4 (en) 2005-08-18 2010-08-04 Glaxo Group Ltd ANTAGONISTS OF ACETYLCHOLINE MUSCARINIC RECEPTORS
GB0921075D0 (en) * 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents

Also Published As

Publication number Publication date
PT1740177E (pt) 2012-11-02
HRP20120832T1 (hr) 2012-11-30
EP1740177A4 (en) 2010-05-05
US9045469B2 (en) 2015-06-02
CA2564742C (en) 2012-01-10
NL300694I2 (pt) 2015-12-29
US20070185155A1 (en) 2007-08-09
CN102040602A (zh) 2011-05-04
MY144753A (en) 2011-10-31
HUS1400053I1 (hu) 2017-07-28
CY2014043I1 (el) 2015-12-09
MXPA06012405A (es) 2007-01-17
LU92565I9 (pt) 2019-01-17
UA95768C2 (ru) 2011-09-12
HUE031304T2 (hu) 2017-07-28
AU2005237576A1 (en) 2005-11-10
PT2570128T (pt) 2016-10-07
PL1740177T3 (pl) 2012-12-31
EA015033B1 (ru) 2011-04-29
EA200601991A1 (ru) 2007-02-27
NL300694I1 (pt) 2015-12-29
PE20060259A1 (es) 2006-03-25
US8575347B2 (en) 2013-11-05
JP2007534769A (ja) 2007-11-29
LU92565I2 (fr) 2014-12-02
JP5014121B2 (ja) 2012-08-29
US20070249664A1 (en) 2007-10-25
US20140080863A1 (en) 2014-03-20
CY1118082T1 (el) 2017-06-28
ES2600405T3 (es) 2017-02-08
US7498440B2 (en) 2009-03-03
JP5398871B2 (ja) 2014-01-29
US7488827B2 (en) 2009-02-10
AU2005237576B2 (en) 2012-01-12
HK1102423A1 (en) 2007-11-23
EP2570128A1 (en) 2013-03-20
AP2213A (en) 2011-03-01
NZ549997A (en) 2010-10-29
CY2014043I2 (el) 2015-12-09
PL2570128T3 (pl) 2017-09-29
EP3111936A1 (en) 2017-01-04
NO338959B1 (no) 2016-11-07
CA2564742A1 (en) 2005-11-10
AP2006003746A0 (en) 2006-10-31
HRP20161385T1 (hr) 2016-12-02
IL178152A (en) 2011-05-31
KR101152032B1 (ko) 2012-06-11
NO2017018I1 (no) 2017-05-04
US20090124653A1 (en) 2009-05-14
SG186597A1 (en) 2013-01-30
CA2755954A1 (en) 2005-11-10
EP1740177A2 (en) 2007-01-10
US8853404B2 (en) 2014-10-07
ZA200608565B (en) 2019-12-18
KR20110010841A (ko) 2011-02-07
WO2005104745A2 (en) 2005-11-10
US20120157491A1 (en) 2012-06-21
DK2570128T3 (en) 2016-11-07
EP1740177B1 (en) 2012-08-08
NO20065417L (no) 2006-12-29
NO2017018I2 (no) 2018-05-14
MA28631B1 (fr) 2007-06-01
SI2570128T1 (sl) 2016-11-30
IL178152A0 (en) 2006-12-31
DK1740177T3 (da) 2012-10-29
EA021994B1 (ru) 2015-10-30
CY1113196T1 (el) 2015-12-09
TWI363759B (en) 2012-05-11
US20140371264A1 (en) 2014-12-18
US20130030015A1 (en) 2013-01-31
ES2392848T4 (es) 2014-10-01
US8183257B2 (en) 2012-05-22
BRPI0510170B1 (pt) 2018-12-18
LT2570128T (lt) 2016-10-10
CN1976701A (zh) 2007-06-06
WO2005104745A3 (en) 2006-08-03
NO2017017I1 (no) 2017-05-04
US9144571B2 (en) 2015-09-29
EP2570128B1 (en) 2016-08-10
UY28871A1 (es) 2005-11-30
AR050902A1 (es) 2006-12-06
SI1740177T1 (sl) 2012-12-31
ES2392848T3 (es) 2012-12-14
KR101037026B1 (ko) 2011-05-25
ECSP066940A (es) 2006-12-20
CA2755954C (en) 2014-02-18
EA201100019A1 (ru) 2011-12-30
KR20070015412A (ko) 2007-02-02
BRPI0510170A (pt) 2007-10-02
US20160002220A1 (en) 2016-01-07
JP2012162559A (ja) 2012-08-30
TW200605887A (en) 2006-02-16
US8309572B2 (en) 2012-11-13
US20150238470A1 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
BRPI0510170B8 (pt) composto, composição farmacêutica para o tratamento de doenças mediadas pelo receptor muscarínico de acetilcolina e uso do composto
BRPI0605921B8 (pt) compostos orgânicos, seus métodos de preparo e uso, bem como composições farmacêuticas
BRPI0415361A (pt) antagonistas do receptor muscarìnico de acetilcolina
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
BRPI0417717A (pt) composto, composição farmacêutica, e, uso de um composto
ATE526318T1 (de) Farnesoid-x-rezeptor-agonisten
CL2004000449A1 (es) Compuestos derivados de imidazol-4-il-etinil-piridina, para tratar trastornos mediados por el receptor mglur5; procedimiento de preparacion de los compuestos; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en
CL2009001274A1 (es) Compuestos derivados de triazina sustituida, mediados por la inhibicion de la kinasa p13 y mtor; composicion farmaceutica; procedimiento de preparacion; y su uso en el tratamiento de diferentes tipos de cancer.
BRPI0606112A2 (pt) 3 - heteroaril - 3 - hidróxi - 2 - amino - propil aminas e compostos relacionados, bem como uso dos mesmos e composição farmacêutica
CR8642A (es) Compuestos, composiciones farmaceuticas y metodos para su uso en el tratameinto de desordenes metabolicos
CL2011001333A1 (es) Compuestos derivados de heterociclos nitrogenados sustituidos, inhibidores de ns5a; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2007002062A1 (es) Compuestos derivado de [1,2,4]triazolo[4,3-a]piridina, inhibidores de quinasa; composicion farmaceutica; y su uso en el tratamiento del cancer.
DK1773885T3 (da) Humaniserede anti-c-met-antagonister
CL2008001946A1 (es) Compuestos derivados de imidazol, antagonistas de receptores ccr2, ccr3, ccr5; procedimiento de preparacion; y uso en el tratamiento de enfermedades vasculares perifericas.
BRPI0614205A2 (pt) composto, composição farmacêutica, e, uso de composto
WO2007027734A3 (en) Bicyclic and bridged nitrogen heterocycles
CL2007002018A1 (es) Compuestos derivados de isoxazolinas sustituidas; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto para el tratamiento de una enfermedad causada por un aumento en la proliferacion celular.
CL2008002097A1 (es) Compuestos derivados de heterociclos condensados sustituidos, inhibidores de cinasa de fosfatidil-inositol-3; composicion farmaceutica; y uso en el tratamiento del cancer.
BRPI0618904A2 (pt) composto, composição farmacêutica, e, uso do composto
CL2009001160A1 (es) Compuestos derivados de heterociclos nitrogenados fusionados y su composicion farmaceutica.
EA200701114A1 (ru) Азоловые производные с антимускариновой активностью
BRPI0506777A (pt) antagonistas do receptor muscarìnico da acetilcolina
CL2011000846A1 (es) Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c.
CL2008002295A1 (es) Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c.
CL2007002207A1 (es) Compuestos derivados de sulfonilaminas; composicion farmaceutica; y uso de los compuestos en el tratamiento del glaucoma.

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GLAXO GROUP LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 18/12/2018, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/04/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF